Document:

<PAGE>
    Confidential Materials omitted and filed separately with the Securities
             and Exchange Commission.  Asterisks denote omissions.

                                                                   EXHIBIT 10.36

                                   ADDENDUM 3
                     OEM Development and Purchase Agreement

Addendum 3 to the agreement dated 22nd day of December, 1999 (the "Agreement"),
by and between Aspect Medical Systems, Inc. ("Aspect") and GE Marquette Medical
Systems, Inc. ("GE").

Per section 7.3 of the Agreement, Purchase Price Reductions, Aspect is reducing
the list price on the BIS/EEG Module Kit (exclusive of the license) by [**]%.
The price Aspect shall charge GE is the following:

      2003: BIS Engine & DSC        $[**]
            License                 $[**]

For the purpose of calculating the volume discount for the calendar year 2003,
all BIS/EEG Module Kits shipped from January 1, 2003 through December 31, 2003
will be included in the total volume discount calculation. List price will be
charged and any volume discount earned will be issued at the time it is earned
either as a credit or cash at the preference of GE.

Aspect is also reducing the list price on Aspect Sensors to $[**] per sensor for
the BIS Quatro, BIS Pediatric and BIS Standard Sensors. In addition, GE will be
eligible for volume discounts off this list price. The volume discount pricing
will be based upon the total volume of BIS Sensors purchased worldwide by GE or
GE subsidiaries during the previous calendar year. For example, the $[**] per
sensor price for 2003 is based on the total volume of sensors purchased during
the period from January 1, 2002 through December 31, 2002.

The attached Exhibit A, dated March 13, 2003, replaces Exhibit A in the
Agreement and any previous addendums to the Agreement.

Please indicate your acceptance of this Addendum by signing below.

Aspect Medical Systems, Inc.              GE Medical Systems, Inc.

By:  /s/ J. Neal Armstrong                By:  /s/ illegible
     ------------------------------            ----------------------------

Title: Chief Financial Officer           Title: Strategic Sourcing-OEM
      -----------------------------            ----------------------------
<PAGE>
                                   ADDENDUM 3
                                    EXHIBIT A
                       ASPECT PRODUCTS AND PURCHASE PRICES
                            EFFECTIVE MARCH 13, 2003

A) ASPECT BIS/EEG MODULE KIT:

      List price for Aspect BIS/EEG Module Kit: $[**] (includes $[**] for
      components and $[**] for BIS license)

      Volume discounts:

<TABLE>
<CAPTION>
     QUANTITY PER      PRICE        PRICE      TOTAL PRICE   DISCOUNT
         YEAR      (COMPONENTS)   (LICENSE)
<S>                 <C>            <C>         <C>           <C>
         [**]         $[**]         $[**]         $[**]       [**]
         [**]         $[**]         $[**]         $[**]       [**]%
         [**]         $[**]         $[**]         $[**]       [**]%
</TABLE>

      GE will be responsible for providing Aspect with documentation, [**], of
      the total number of GE BIS/EEG Modules installed [**], the locations of
      such GE BIS/EEG Modules and the dates of installation.

B) ASPECT BIS SENSORS

   Volume discounts:

<TABLE>
<CAPTION>
                 QUANTITY PER YEAR          PRICE
<S>                                         <C>
                       [**]                 $[**]
                       [**]                 $[**]
                       [**]                 $[**]
                       [**]                 $[**]
</TABLE>

      Pricing applicable to the BIS Quatro Sensor, BIS Pediatric Sensor and BIS
      Standard Sensor.
<PAGE>
C) ASPECT SPARE PARTS/ACCESSORY PRICES
<TABLE>
<CAPTION>
              ORDERABLE        ASPECT LIST PRICE      GE PRICE (US$)
           PARTS/PRODUCTS            (US$)
<S>                            <C>                    <C>
        DSC-XP (replacement)         $[**]                $ [**]
        BIS Engine PCB               $[**]                $ [**]
        (replacement)A

        Sensor Cable                 $[**]                $ [**]
        (replacement)
        DSC-4 (replacement)          $[**]                $ [**]
        User Manual                  $[**]                $ [**]
</TABLE>

      Note A: assumes imputed BIS license fee of $[**] per unit for BIS Engine
      PCB<PAGE>

                                                                  Exhibit 10.6.1

                              AMENDED AND RESTATED
                  RESEARCH, DEVELOPMENT AND LICENSE AGREEMENT

         This Agreement, effective as of January 1, 2001 (the "Effective Date"),
is between ArQule, Inc. ("ArQule"), a Delaware corporation, and Solvay
Pharmaceuticals B.V. ("Solvay"), a Dutch corporation.

                                R E C I T A L S

         WHEREAS, the parties previously entered into that certain Research,
Development and License Agreement, effective as of November 2, 1995 (the "Prior
Agreement");

         WHEREAS, the Prior Agreement will, by its terms, expire on December 31,
2000; and

         WHEREAS, the parties desire to continue certain activities under the
Prior Agreement and to continue their collaboration by undertaking additional
research and development activities;

         NOW, THEREFORE, in consideration of the mutual covenants set forth in
this Agreement, the parties hereby agree as follows:

1.       Definitions.

         1.1.     "Active Compound" shall mean an ArQule Compound that has
exhibited biological activity against a Target and as to which Solvay has
provided the required notice to ArQule under the Prior Agreement or under this
Agreement pursuant to Sections 3.2. and 3.4

         1.2.     "Affiliate" shall mean a corporation or other legal entity
that controls, is controlled by, or is under common control with such party. For
purposes of this definition, control means the ownership, directly or
indirectly, of fifty percent (50%) or more of the outstanding equity securities
of a corporation which are entitled to vote in the election of directors or a
fifty percent (50%) or greater interest in the net assets or profits of an
entity which is not a corporation.

         1.3.     "Agreement" shall mean this Research, Development and License
Agreement, together with Exhibits A and B hereto.

         1.4.     "ArQule Compound" shall mean a chemical compound provided by
ArQule to Solvay pursuant to this Agreement or under the Prior Agreement as part
of a screening library including, without limitation, the compounds provided in
the Compass Array Library and Mapping Array Libraries.

<PAGE>

         1.5.     "ArQule Derivative Compound" shall mean a Derivative Compound
developed from a Licensed Compound by ArQule or by or for Solvay in the course
of an optimization program for the molecular Target or other Target (e.g., whole
cell screen) against which such Licensed Compound was initially discovered to
have biological activity, i.e., a compound is not an ArQule Derivative Compound
if that compound is independently developed by Solvay.

         1.6.     "Array" shall mean a set of samples of structurally related
chemical compounds arranged in a format such as a microtiter screening plate.

         1.7.     "Available Compound" shall mean an Active Compound which
ArQule has determined is not (i) licensed or otherwise committed to a third
party in the Field or (ii) committed to an internal ArQule program in the Field
and is reserved to Solvay on an exclusive basis pursuant to Section 3.

         1.8.     "Chemical Theme" shall mean the chemical or structural
characteristics shared by (i) the ArQule Compounds in a Mapping Array Library or
(ii) a group of compounds in a Directed Array Library as determined by the
Research Committee pursuant to Section 2.2.1.

         1.9.     "Compass Array(TM) Library" shall mean a collection of ArQule
Compounds that is a diverse representative subset of the Mapping Array Libraries
produced in calendar year 2001 and used for initial screening of those Mapping
Array Libraries. The description of, and the specifications for, the Compass
Array Library are set forth in Exhibit A attached hereto.

         1.10.    "Confidential Information" shall have the meaning set forth in
Section 10.1.1.

         1.11.    "Derivative Compound" shall mean a chemical compound that was
structurally derived from a parent ArQule Compound or Solvay Compound in one or
more steps by a process of modification or partial substitution of at least one
component wherein at least one structural feature is retained at each process
step. The number of intermediate steps or compounds is not relevant to the
classification of a compound as a Derivative Compound. A compound need not have
structural similarity to another compound in order to be classified as a
Derivative Compound.

         1.12.    "Directed Array(R) Library" shall mean an Array comprised of
Derivative Compounds synthesized by ArQule under the Directed Array Program. The
description of, and the specifications for, the Directed Array Libraries are set
forth in Exhibit A attached hereto.

         1.13.    "Directed Array(R) Program" or "DA Program" shall mean the
Directed Array Library component of the Research Program conducted by ArQule for
Solvay in general accordance with the Research Plan, as set forth in Section 4.

         1.14.    "Field" shall mean applications in the life sciences.

         1.15.    "Full-Time Equivalent" or "FTE" shall mean one (1) or more
employees of ArQule who, collectively, spend time and effort working on a
specific project or task equivalent

                                       2

<PAGE>

to the time and effort of one (1) full-time employee working on such project or
task (approx. 2,000 hours per year).

         1.16.    "Licensed Compound" shall mean (i) any Available Compound
that, as of the Effective Date, has already been designated as a Licensed
Compound under the Prior Agreement or (ii) any Available Compound that the
Research Committee designates as a Licensed Compound in accordance with Section
3.6.

         1.17.    "Licensed Compound Set" shall mean a set of one or more
Licensed Compounds from the same Mapping Array Library that have biological
activity for the same Target.

         1.18.    "Mapping Array(R) Library" shall mean an Array of ArQule
Compounds which ArQule makes available to its collaborators for screening on a
non-exclusive basis. ArQule previously delivered Mapping Array Libraries to
Solvay under the Prior Agreement. The description of, and the specifications
for, the Mapping Array Libraries that ArQule will deliver to Solvay under
Article 3 of this Agreement are set forth in Exhibit A attached hereto.

         1.19.    "Mapping Array(R) Program" or "MA Program" shall mean the
component of the Research Program under which ArQule previously provided to
Solvay under the Prior Agreement with Mapping Array Libraries. Under this
Agreement ArQule will provide Solvay with a portion of the Compass Array Library
and with selected Mapping Array Libraries, as further described in Section 3.

         1.20.    "Net Sales" shall mean the aggregate Net Sales Price of
Royalty-Bearing Products in any Royalty Period.

         1.21.    "Net Sales Price" shall mean the gross amount received on
sales by Solvay, its Affiliates and sublicensees of Royalty-Bearing Products in
the Field, less the following: (i) trade, quantity, and cash discounts or
rebates actually allowed, (ii) credits or allowances given for rejections or
returns, (iii) freight, shipping, or other costs of transportation including
insurance costs charged to a customer, and (iv) to the extent separately stated
on purchase orders, invoices, or other documents of sale, any taxes (e.g.,
excise tax, duties, VAT) levied on the sale of a Royalty-Bearing Product which
is paid by Solvay or its Affiliates or sublicensees. In any transfers of
Royalty-Bearing Products between Solvay and an Affiliate, the Net Sales Price
shall be calculated based on the first sale of the Royalty-Bearing Product to an
independent third party. In the event that Solvay receives non-monetary
consideration for any Royalty-Bearing Products, the Net Sales Price shall be
calculated based on the average price charged by Solvay for such Royalty-Bearing
Products during the preceding Royalty Period.

         1.22.    "Patent Rights" shall mean all issued patents and reissues,
reexaminations, extensions and supplementary protection certificates thereof and
all patent applications and any divisions, continuations, or
continuations-in-part thereof (to the extent directed to the subject matter of
the parent application) or patents issuing thereon. "ArQule Patent Rights" means
Patent Rights that are either (i) assigned solely to ArQule, (ii) assigned
jointly to ArQule and a party other than Solvay, or (iii) licensed to or
otherwise controlled by ArQule, in each case to the extent that ArQule has the
ability to license or sublicense the rights required under this

                                       3
<PAGE>

Agreement without payment to a third party. "Solvay Patent Rights" means Patent
Rights that are either (i) assigned solely to Solvay, (ii) assigned jointly to
Solvay and a party other than ArQule, or (iii) licensed to or otherwise
controlled by Solvay, in each case to the extent that Solvay has the ability to
license or sublicense the rights required under this Agreement without payment
to a third party. "Joint Patent Rights" means Patent Rights assigned to both
ArQule and Solvay as joint owners in relation to Joint Technology. Explicitly
excluded are rights in the compounds specified in Section 6.1. Joint Patent
Rights will include (i) Patent Rights claiming Joint Technology and (ii) Patent
Rights claiming both ArQule Technology and Solvay Technology in a single filing.

         1.23.    "Phase II Clinical Trials" shall mean clinical trials in a
small sample of the intended patient population commencing on the filing of a
trial protocol with the appropriate regulatory authority to assess the efficacy
for a specific indication of a compound proposed to be used as a prophylactic,
therapeutic or diagnostic pharmaceutical product, to determine dose tolerance
and the optimal dose range as well as to gather additional information relating
to safety and potential adverse effects, and meeting the requirements
established by the U. S. Food and Drug Administration for Phase II clinical
trials.

         1.24.    "Phase III Clinical Trials" shall mean clinical trials
designed to demonstrate safety and efficacy of a compound proposed to be used as
a prophylactic, therapeutic or diagnostic pharmaceutical product in an expanded
patient population at geographically dispersed study sites, meeting the
requirements established by the U.S. Food and Drug Administration for Phase III
clinical trials.

         1.25.    "Priority Substance" shall mean a compound under this
Agreement selected by Solvay or an Affiliate of Solvay to enter into the
preclinical research phase.

         1.26.    "Project Declaration" shall mean, with respect to a compound
under this Agreement, the decision to commence human clinical trials.

         1.27.    "Proprietary Materials" shall have the meaning set forth in
Section 10.2.1.

         1.28.    "Research Committee" shall mean the Research Committee
described in Section 2.

         1.29.    "Research Period" shall mean the period commencing on the
Effective Date and continuing through December 31, 2003.

         1.30.    "Research Plan" shall mean a plan of research for the DA
Program covering a six-month period, which shall be updated quarterly pursuant
to Section 2.2 to reflect developments during the previous three (3) months and
extended for the subsequent three (3) months.

         1.31.    "Research Program" shall mean, collectively, the Directed
Array Program and the Mapping Array Program.

                                       4
<PAGE>

         1.32.    "Royalty-Bearing Product" shall mean a product containing as
one of its constituents (i) any Licensed Compound; (ii) any ArQule Derivative
Compound; (iii) any Solvay Derivative Compound; or (iv) any other compound
discovered or designed by Solvay directly as a result of information obtained by
Solvay under the MA Program or DA Program from one or more Licensed Compounds or
Derivative Compounds, which information forms the primary basis for such
discovery or development and which information was not previously known to
Solvay from sources other than ArQule.

         1.33.    "Royalty Period" shall mean every calendar quarter, or partial
calendar quarter, in which a royalty is payable to ArQule pursuant to Section
9.5. commencing with the first commercial sale of a Royalty-Bearing Product in
any country.

         1.34.    "Solvay Compound" shall mean any chemical compound provided by
Solvay or its Affiliates to ArQule under the Prior Agreement or in the Directed
Array Program under this Agreement.

         1.35.    "Solvay Derivative Compound" shall mean a Derivative Compound
developed from a Solvay Compound by ArQule under the Prior Agreement or in the
Directed Array Program under this Agreement, as well as Derivative Compounds
thereof developed or by or for Solvay.

         1.36.    "Target" shall mean the biological target against which
activity of an Active Compound was revealed, together with any related
biomolecules that (i) (A) exhibit substantial structural homology with the
identified biomolecule, as measured by the degree of similarity in the primary
structure (i.e., amino acid sequence, nucleotide sequence, monosaccharide
linkages) and secondary structure (i.e., three-dimensional structure), or (B)
perform a substantially similar function as the identified biomolecule, and (ii)
have therapeutic relevance. Biological targets shall not be considered as
exhibiting substantial structural homology nor functional similarity if such
biological targets are generally recognized by the scientific community as being
different.

         1.37.    "Technology" shall mean any proprietary development,
information, know-how, idea, design, concept, technique, process, invention,
compound, discovery, improvement whether or not patentable or copyrightable.
"ArQule Technology" means Technology that is either (i) assigned solely to
ArQule, (ii) assigned jointly to ArQule and a party other than Solvay, or (iii)
licensed to or otherwise controlled by ArQule, in each case to the extent that
ArQule has the ability to license or sublicense the rights required under this
Agreement without payment to a third party. "Solvay Technology" means Technology
that is either (i) assigned solely to Solvay, (ii) assigned jointly to Solvay
and a party other than ArQule, or (iii) licensed to or otherwise controlled by
Solvay, in each case to the extent that Solvay has the ability to license or
sublicense the rights required under this Agreement without payment to a third
party. "Joint Technology" means Technology that is developed or discovered
jointly by one or more employees or consultants of Solvay and one or more
employees or consultants of ArQule pursuant to this Agreement, explicitly
excluded are the compounds specified in Section 6.1.

         1.38.    "Valid Claim" means either (i) a claim of an issued patent
that has not been held unenforceable or invalid by an agency or a court of
competent jurisdiction in any unappealable

                                       5
<PAGE>

or unappealed decision or (ii) a claim of a pending patent application that has
not been abandoned or finally rejected without the possibility of appeal or
refiling.

         1.39.    The above definitions are intended to encompass the defined
terms in both the singular and plural tenses.

2.       Management of Research Programs.

         2.1.     Composition of Research Committee. The parties hereby
establish a Research Committee comprised of six (6) members, with three (3)
representatives appointed by each party. A party may change one or more of its
representatives to the Research Committee at any time upon notice to the other
party.

         2.2.     Duties of the Research Committee. The Research Committee shall
direct and administer the Research Program in general accordance with the
following provisions:

         2.2.1.   DA Program. With respect to the DA Program, the Research
Committee has heretofore determined the general specifications for the Directed
Array Libraries to be delivered to Solvay during the Research Period. ArQule
shall have the right, at the time Solvay seeks to include any compound(s) in the
DA Program, to exclude from the DA Program any compound that ArQule has
determined is (i) licensed or otherwise committed to a third party in the Field
or (ii) committed to an internal ArQule program in the Field. The Solvay
representatives on the Research Committee shall, in consultation with the ArQule
representatives, determine the identity, scope and priority of each Chemical
Theme. The identity and scope of such Chemical Theme will be determined on the
basis of the following criteria: (i) the specific reaction or reaction sequence
used to combine members of two or more discrete chemical units in which each
chemical unit bears the functional group(s) required for the specific
reaction(s) that result in the combination of the chemical units; and (ii) the
extent to which a class of compounds is related by a recurring structural motif
associated with a particular biological activity.

         2.2.2.   Other Responsibilities. In addition, the Research Committee
shall (i) revise and extend the Research Plan each calendar quarter for the
subsequent six (6) months based on prior developments, (ii) designate Available
Compounds as Licensed Compounds as described in Section 3.6; (ii) maintain and
update the list of Licensed Compounds and Licensed Compound Sets; (iii)
determine the allocation of the funding and personnel resources to be
contributed by ArQule for the Directed Array Program; and (iv) resolve matters
involving scientific questions and publication disputes that may arise under
Section 10.4.

         2.3.     Meetings of the Research Committee. The Research Committee
shall conduct telephone conferences at least once every six (6) weeks and shall
prepare and deliver a brief written report (which may be in the form of
confirmed electronic mail) describing the significant issues and discussions
that take place during such telephone conferences. A representative of the
Research Committee jointly appointed by its members shall provide each member
with five (5) business days notice of the time of telephone conferences, unless
such notice is waived by all members. ArQule will prepare and deliver to the
members of the Research Committee a brief

                                       6
<PAGE>

progress report at least one week in advance of the telephone conference, which
report will list the ArQule employees then working on the Research Program. The
Research Committee shall meet at least twice each year with the location
alternating between the ArQule site and the Solvay site, or at such other times
and locations as the Research Committee determines. A representative of the
Research Committee jointly appointed by its members shall provide each member
with five (5) business days notice of the time and location of meetings, unless
such notice is waived by all members. If a designated representative of a party
cannot attend any meeting of the Research Committee, such party may designate a
different representative for that meeting without notice to the other party, and
the substitute member will have full power to vote on behalf of the permanent
member. Except as otherwise provided in this Section 2, all actions and
decisions of the Research Committee will require the unanimous consent of all of
its members. If the Research Committee fails to reach agreement upon any matter,
the dispute will be resolved in accordance with the procedures set forth in
Section 13.5 below. Within fourteen (14) days following each meeting, the
Research Committee shall prepare and deliver, to both parties, a written report
describing the decisions made, conclusions and actions agreed upon.

         2.4.     Cooperation. Each party agrees to provide the Research
Committee with information and documentation as reasonably required for the
Research Committee to fulfill its duties under this Agreement. In addition, each
party agrees to make available its employees and consultants as reasonably
requested by the Research Committee. The parties anticipate that members of the
Research Committee will communicate informally with each other and with
employees and consultants of the parties on matters relating to the Research
Programs.

         2.5.     Visits to Facilities. Members of the Research Committee shall
have reasonable access to the facilities of each party where activities under
this Agreement are in progress, but only during normal business hours and with
reasonable prior notice. Each party shall bear its own expenses in connection
with such site visits.

3.       Mapping Array Program.

         3.1.     Prior Agreement. Solvay acknowledges that ArQule has fully
performed and discharged its obligations under Section 3.1. of the Prior
Agreement. ArQule acknowledges that Solvay has fully satisfied and discharged
its obligations under Section 3.2. of the Prior Agreement. Solvay acknowledges
and agrees ArQule remains eligible to receive milestone and royalty payments on
Royalty-Bearing Products as set forth in this Agreement. Solvay and ArQule
expressly acknowledge and agree that the provisions of this Agreement supersede
the provisions of the Prior Agreement with respect to the Mapping Array Program.

         3.2.     Compass Array Library. ArQule will supply Solvay with one (1)
copy of the Compass Array Library corresponding to Mapping Array Libraries
produced in calendar year 2001 in four (4) quarterly portions promptly after
such ArQule Compounds become available, with the last shipment delivered not
later than July 1, 2002. ArQule will not disclose the structures of individual
ArQule Compounds in the Compass Array Library and Solvay will have no obligation
to disclose its Targets. ArQule will disclose to Solvay the Chemical Themes in
the Compass Array Library in Markush format. Solvay will diligently screen the
Compass Array

                                       7
<PAGE>

Library against its selected Targets. When Solvay detects and confirms Active
Compounds in the Compass Array Library, Solvay will inform ArQule through the
Research Committee.

         3.3.     Selection of Mapping Array Libraries. During the Research
Period, ArQule will promptly determine whether the Active Compounds identified
by Solvay in the Compass Array Library are Available Compounds, and then notify
Solvay of such determination. If any Active Compound is not an Available
Compound, ArQule shall not disclose the structure and Solvay shall have no
rights under this Agreement with respect to that Active Compound. If an Active
Compound is an Available Compound, ArQule shall reserve such Available Compound
to Solvay under this Agreement. ArQule then shall disclose to Solvay the
structure of such Available Compound correlated to its well location and its
Mapping Array Library. ArQule shall maintain the reserved status of the
Available Compound for a period of up to four (4) weeks after the date upon
which the structure was disclosed to Solvay. All such disclosed structures shall
be treated as ArQule Confidential Information. During the four-week reservation
period, Solvay will confirm its interest in that Available Compound and may
request the Mapping Array Library for that Available Compound (if Solvay does
not already have that Mapping Array Library in its possession) upon written
notice to ArQule (including by electronic mail). If Solvay does not confirm its
interest in writing and does not request the Mapping Array Library for that
Available Compound (if that Mapping Array Library is not already in the
possession of Solvay) during the four-week reservation period, the Available
Compound shall automatically lose its reserved status and Solvay shall have no
further rights to such compound. ArQule will promptly deliver to Solvay the
selected Mapping Array Libraries; provided, however, that ArQule will have no
obligation to deliver more than one (1) copy of each Mapping Array Library
pursuant to this Agreement. In addition, with each shipment of a Mapping Array
Library, or upon confirmation of interest by Solvay in the case of a Mapping
Array Library already in the possession of Solvay, ArQule will furnish Solvay
with (i) the Chemical Theme of the Mapping Array Library in Markush format, (ii)
the location of each Available Compound in the Mapping Array Library, and (iii)
at the request of Solvay, the locations (but not the structures) of ArQule
Compounds that are the nearest homologues to the Available Compounds (under
procedures established by the Research Committee) and which are not licensed or
otherwise committed to a third party in the Field or committed to an internal
ArQule program in the Field. ArQule shall not identify the structures of the
individual ArQule Compounds in the Mapping Array Libraries.

         3.4.     Mapping Array Library. Upon receipt of each Mapping Array
Library, or upon receipt of the relevant information as described in Section
3.3. in the case of Mapping Array Libraries already in the possession of Solvay,
Solvay shall diligently screen such Mapping Array Library for activity against
the relevant Target(s). ArQule will maintain the reserved status of the
Available Compound(s) identified in the Compass Array Library for a period of
four (4) months after Solvay receives the relevant Mapping Array Library and
accompanying information or, in the case of Mapping Array Libraries already in
the possession of Solvay, for a period of four (4) months after Solvay receives
the relevant information as described in Section 3.3. In addition, Solvay shall
have the right to screen all Mapping Array Libraries in its possession
irrespective of the Compass Array Library. If Solvay detects and confirms Active
Compounds, Solvay shall inform ArQule through the Research Committee in writing
(including by electronic mail) of the spatial location of Active Compounds in
the Mapping Array Libraries. ArQule will promptly determine whether the Active
Compounds identified by Solvay in the Mapping Array

                                       8
<PAGE>

Libraries are Available Compounds, and then notify Solvay of such determination.
If any Active Compound is not an Available Compound, ArQule shall not disclose
the structure and Solvay shall have no rights under this Agreement with respect
to that Active Compound. If an Active Compound is an Available Compound, ArQule
shall reserve such Active Compound as an Available Compound to Solvay under this
Agreement. ArQule then shall disclose to Solvay the structure of such Available
Compound correlated to its well location, and Solvay shall disclose to ArQule
the class of the Target involved. All such disclosed structures and the target
class shall be treated as Confidential Information. ArQule shall maintain the
reserved status of every Active Compound that is an Available Compound from the
same Mapping Array Library for a period of up to four (4) weeks after the date
upon which the last structure of these Available Compounds is disclosed to
Solvay. If Solvay requests resynthesis of one or more Available Compounds from
the same Mapping Array Library during the four-week reservation period, the
Research Committee will determine which of these Available Compounds if not all
would become a Licensed Compound Set if the resynthesized compounds are
confirmed to be Active Compounds, and ArQule will continue to reserve this group
of Available Compounds, all as more fully described below. The Research
Committee will resolve any disagreements regarding which Available Compounds
constitute the "group" represented by the compound or compounds resynthesized.
If the four-week reservation period expires for a group of Available Compounds
without any resynthesis request by Solvay or without agreement by the Research
Committee as to which Available Compounds should constitute the group pending
resynthesis and confirmation, the other Available Compounds (i.e., Available
Compounds that are not selected for resynthesis by Solvay) from that Mapping
Array Library shall automatically lose their reserved status and Solvay shall
have no further rights to such compounds.

         3.5.     Resynthesis. During the Research Period, ArQule shall
resynthesize and deliver to Solvay an additional 25 mg quantity of any Available
Compound requested by Solvay to enable Solvay to conduct confirmatory screening
activities. Solvay shall provide ArQule with written notice of the Available
Compounds that Solvay desires to have resynthesized by ArQule. ArQule shall
resynthesize the requested compounds in accordance with the specifications set
forth in Exhibit A. In each case the actual amount of, and delivery schedule
for, resynthesized Available Compounds will be determined by the Research
Committee. ArQule will maintain the reservation on each group of Available
Compounds (as determined by the Research Committee under Section 3.4.) while
ArQule prepares resynthesis quantities of selected Available Compounds from that
group and will then continue to reserve that group of Available Compound for a
period of up to three (3) months after Solvay receives the resynthesized
Available Compounds.

         3.6.     Designation of Licensed Compounds. At the request of Solvay,
the Research Committee will review and consider the pertinent confirmatory data
with respect to each group of Available Compounds (as determined by the Research
Committee under Section 3.4.) and, if the activity of the resynthesized compound
or compounds has been confirmed, designate the Available Compounds within the
group as "Licensed Compounds" under this Agreement, whereupon Solvay shall
disclose the Target and level of activity for the Licensed Compounds and, at the
request of Solvay, ArQule shall disclose the structures but not the locations of
the other ArQule Compounds in the same Mapping Array Library as the Licensed
Compounds. Upon the designation of an Available Compound as a Licensed Compound
and the disclosure by

                                       9
<PAGE>

Solvay of the Target and level of activity, the licenses set forth in Section
7.2 shall automatically apply, and ArQule shall confirm such license in writing.
If the Research Committee determines that the activity of the resynthesized
compound or compounds has not been confirmed, then the Available Compounds
within the group shall automatically lose their reserved status and Solvay shall
have no further rights to such compounds.

         3.7.     Changes to Reservation Periods. The Research Committee may
extend the reservation periods described in Sections 3.3., 3.4., and 3.5. if
requested by Solvay and approved in writing by the Chief Scientific Officer of
ArQule.

         3.8.     Optimization Rights. During the Research Period, Solvay may
submit any Licensed Compound Set to ArQule for optimization in the Directed
Array Program; however, ArQule has no obligation to increase its commitment to
the Directed Array Program as set forth in Section 4.3. At any time, Solvay may
conduct optimization of any Licensed Compound Set. In the event that Solvay
conducts optimization of a Licensed Compound Set, then at the request of Solvay,
ArQule will provide Solvay with synthetic protocols (in American Chemical
Society experimental format, not automated protocols) to enable Solvay to make
those Licensed Compounds.

         3.9.     Extension Right. If ArQule continues to offer the Mapping
Array Program during the year 2002, Solvay may extend on the same terms the
supply of ArQule Compounds in the form of the Compass Array Library and the
Mapping Array Libraries through December 31, 2002 upon written notice to ArQule
which is received by ArQule not later than October 1, 2001. In addition, ArQule
and Solvay agree to negotiate in good faith an arrangement under which Solvay
may screen the Mapping Array Compounds and have access to the structures of
Active Compounds after the conclusion of the Research Period.

4.       Directed Array Program.

         4.1.     Prior Agreement. Solvay acknowledges that ArQule has fully
satisfied and discharged its obligations under Sections 4.1. and 4.2. of the
Prior Agreement. ArQule acknowledges that Solvay has fully satisfied and
discharged its obligations under Section 4.3. of the Prior Agreement. Solvay
acknowledges and agrees ArQule remains eligible to receive milestone and royalty
payments on Royalty-Bearing Products as set forth in this Agreement. Solvay and
ArQule expressly acknowledge and agree that the provisions of this Agreement
supersede the provisions of the Prior Agreement with respect to the Directed
Array Program.

         4.2.     Description of Program. Under the direction of the Research
Committee and in accordance with the Research Plan, ArQule will synthesize
multiple Directed Array Libraries of compounds derived from (i) Solvay Compounds
provided to ArQule by Solvay or (ii) Licensed Compounds requested by Solvay to
be included in the DA Program. The parties intend that, during the Research
Period, ArQule will produce such Directed Array Libraries based on approximately
ten (10) different Chemical Themes each calendar year, which will result in the
production of up to 1,000 Derivative Compounds per Chemical Theme per year;
provided, however, that the number of Chemical Themes actually submitted to the
DA Program and the number of Derivative Compounds actually produced per Chemical
Theme will be determined by

                                       10
<PAGE>

the Research Committee. The parties also intend that ArQule will produce
approximately twenty (20) milligrams of each Derivative Compound in the Directed
Array Libraries, subject to the availability of the original Solvay Compounds or
Licensed Compounds; the amount of each Derivative Compound that ArQule actually
produces, however, will be determined by the Research Committee. ArQule agrees
that any Derivative Compounds provided to Solvay under the DA Program will not
be (i) licensed or otherwise committed to a third party in the Field or (ii)
committed to an internal ArQule program in the Field, and Solvay agrees that
ArQule may exclude from the DA Program any Derivative Compounds that ArQule has
determined are (i) licensed or otherwise committed to a third party in the Field
or (ii) committed to an internal ArQule program in the Field.

         4.3.     Conduct of Directed Array Program. The DA Program will be
conducted in accordance with the Research Plan. ArQule shall commit a total of
four (4) FTEs per calendar year to the Directed Array Program (including at
least two full-time synthetic organic chemists). ArQule shall furnish Solvay
with a quarterly report describing progress and methods used in sufficient
detail and that includes the names of the synthetic organic chemists and the
time spent in the DA Program in that quarter, as well as the total non-chemist
FTE resource applied to the DA Program in that quarter with an approximate
breakdown by function. Solvay shall propose projects to the Research Committee
for inclusion as a Directed Array Program. If the Research Committee approves
the inclusion of the proposed project, ArQule shall thereupon diligently
synthesize Directed Array Libraries of ArQule Derivative Compounds or Solvay
Derivative Compounds in accordance with the Research Plan; Solvay shall provide
ArQule with the requisite amount and purity of Solvay Compounds, as directed by
the Research Committee, for any Directed Array Library Programs based on such
Solvay Compounds. Solvay shall, in its discretion, test all compounds in the
Directed Array Libraries. The parties shall perform the Directed Array Programs
under this Agreement during the first two (2) years of the Research Period.
ArQule shall have no obligation to expand or extend its commitments to the
Directed Array Program, including without limitation the commitment of four (4)
FTEs per calendar year and the two-year performance period.

5.       Ownership of Physical Compounds.

         ArQule acknowledges and agrees that all Solvay Compounds, Solvay
Derivative Compounds, and ArQule Derivative Compounds are Solvay Proprietary
Materials and, as such, are owned by Solvay. Solvay acknowledges and agrees that
all ArQule Compounds are ArQule Proprietary Materials and, as such, are owned by
ArQule.

6.       Intellectual Property Rights.

         6.1.     Rights in Compounds. Solvay shall have the sole right to
prepare, file, prosecute, and maintain Patent Rights that claim the composition
or use of (i) ArQule Derivative Compounds or Solvay Derivative Compounds
developed by either party under this Agreement and (ii) Licensed Compounds that
come within the scope of the claims to ArQule Derivative Compounds under clause
(i) above, provided that such Licensed Compounds are not already covered by a
claim in an ArQule Patent Right. ArQule shall assign to Solvay all right, title,
and interest in any Patent Rights filed by Solvay that claim the composition or
use of such ArQule

                                       11
<PAGE>

Derivative Compounds, Solvay Derivative Compounds, or Licensed Compounds.
Therefore, such Patent Rights are considered Solvay Patent Rights under this
Agreement rather than Joint Patent Rights, and Solvay shall be the sole owner of
such Patent Rights. ArQule shall not in any way seek to rely on any ArQule
Patent Right or other intellectual property right in the ArQule Technology to
prevent Solvay from exercising its rights under this Section 6.1.

         6.2      Ownership of Patent Rights and Technology. Other than as
expressly provided herein, neither party shall have any rights in Patent Rights
and Technology that is invented, developed or discovered by the other party
prior to the Effective Date subject to the provisions of the Prior Agreement or
outside the research performed under this Agreement. Ownership of Patent Rights
and Technology arising from the research performed under this Agreement shall be
allocated in the following manner:

         (i)      ArQule shall have sole ownership of all right, title, and
                  interest in ArQule Patent Rights and ArQule Technology,
                  subject to the licenses granted to Solvay under Section 7.1.
                  and Section 7.2.;

         (ii)     Solvay shall have sole ownership of all right, title, and
                  interest in Solvay Patent Rights and Solvay Technology; and

         (iii)    ArQule and Solvay shall have joint ownership of all right,
                  title, and interest in Joint Patent Rights and Joint
                  Technology.

         6.3.     Management of Patent Rights. Solvay shall have sole
responsibility for, and control over, the management of Solvay Patent Rights and
ArQule shall have sole responsibility for, and control over, the management of
ArQule Patent Rights. Each party will bear its own expenses in connection with
such Patent Rights. In the case of Joint Patent Rights, the parties shall agree
on the allocation of responsibility for, and the expense of, the preparation,
filing, prosecution, and maintenance of any Joint Patent Rights claiming such
inventions as decided by the Research Committee. In the event of any
disagreement concerning any Joint Patent Rights, the matter shall be resolved by
the CEO of ArQule and the Vice President-Research of Solvay. The party
controlling a Joint Patent Right shall consult with the other party as to the
preparation, filing, prosecution, and maintenance of such Joint Patent Right
reasonably prior to any deadline or action with the U.S. Patent & Trademark
Office or any foreign patent office, and shall furnish to the other party copies
of all relevant documents reasonably in advance of such consultation. In the
event that the party controlling a Joint Patent Right desires to abandon such
Joint Patent Right, or if the party assuming control of a Joint Patent Right
later declines responsibility for such Joint Patent Right, the controlling party
shall provide reasonable prior written notice to the other party of such
intention to abandon or decline responsibility, and such other party shall have
the right, at its expense, to prepare, file, prosecute, and maintain such Joint
Patent Rights.

         6.4.     Cooperation of the Parties. Each party agrees to cooperate
fully in the preparation, filing, and prosecution of any Patent Rights under
this Agreement and any potential infringement issues relating to ArQule
Technology. Such cooperation includes, but is not limited to:

                                       12
<PAGE>

                  (a)      executing all papers and instruments, or requiring
its employees or agents, to execute such papers and instruments, so as to
effectuate the ownership of Patent Rights set forth in Section 6.1 above and to
enable the other party to apply for and to prosecute patent applications in any
country;

                  (b)      promptly informing the other party of any matters
coming to a party's attention that may affect the preparation, filing, or
prosecution of any such patent applications or potential infringement issues
relating to the ArQule Technology; and

                  (c)      undertaking no actions that are potentially
deleterious to the preparation, filing, or prosecution of such patent
applications.

         6.5      Representation. ArQule represents and warrants to Solvay that,
to the best of ArQule's knowledge and belief, no claim of ownership, invalidity
or patent infringement has been asserted against ArQule or its Affiliates with
respect to ArQule Patent Rights or ArQule Technology as of the Effective Date.
In addition, ArQule covenants that, during the Research Period, ArQule will use
its best efforts to ensure that the practice of the combinatorial library
design, synthesis, and analysis technology within the ArQule Technology
(commonly referred to and collectively defined herein as the "AMAP Chemistry
Operating System") will not infringe any Valid Claim of any Patent Right of a
third party in a manner that would have a material adverse effect on Solvay as a
result of the activities undertaken by ArQule under Articles 3 and 4 of this
Agreement. Solvay acknowledges and agrees that the representations and
warranties set forth in this Section 6.5. have effect only in connection with
the activities undertaken by ArQule under Articles 3 and 4 of this Agreement and
have no effect with respect to the transfer of AMAP Technology under Article 8
of this Agreement.

         6.6.     Infringement.

                  6.6.l.   Offensive Actions. With respect to infringement of
any Solvay Patent Right or any ArQule Patent Right or Joint Patent Right
exclusively licensed to Solvay claiming the composition or use of a Licensed
Compound, ArQule Derivative Compound, or Royalty-Bearing Product, Solvay shall
have the primary right, but not the obligation, to enforce such Patent Right
under its sole control and at its sole expense. In such event, Solvay shall be
exclusively entitled to all proceeds or recoveries resulting therefrom, but from
such proceeds or recoveries Solvay shall pay ArQule a royalty in accordance with
Section 9.5. on sales lost to the infringer after deduction of all costs,
including reasonable attorney fees incurred by Solvay in the action to enforce
such Patent Rights. In the event that Solvay declines to enforce such Patent
Right with respect to a Royalty-Bearing Product where the sales of the alleged
infringer are at least twenty percent (20%) of the market for said product, then
ArQule shall have the secondary right to enforce such Patent Right under its
sole control and at its sole expense. In such event, ArQule shall be exclusively
entitled to all proceeds or recoveries resulting therefrom.

                  6.6.2.   Defensive Actions. Solvay will indemnify, defend, and
hold harmless ArQule, its Affiliates, and their respective officers, directors,
employees, and agents from any and all loss, damage, cost, and expense
(including reasonable attorneys fees) and amounts paid in settlement arising
from any actual or alleged infringement claim brought by a third party, in law

                                       13
<PAGE>

or in equity, based on activities undertaken by Solvay or by ArQule at the
direction of Solvay (except for claims based solely on the practice of an ArQule
Patent Right or the use of ArQule Technology) or based on the manufacture or
sale of a Royalty-Bearing Product. In the event that ArQule intends to claim
indemnification under this Subsection, ArQule shall promptly notify Solvay of
the infringement action and Solvay shall assume the defense of the action under
its sole control, including the right to effect a settlement. A failure by
ArQule to deliver notice to Solvay within a reasonable time shall relieve Solvay
of its indemnity obligation under this Section to the extent such failure
prejudices the ability of Solvay to defend such action. ArQule shall cooperate
fully with Solvay and its legal representatives in the investigation and defense
of the action. In the event of a settlement, Solvay shall obtain the consent of
ArQule before agreeing to any settlement that imposes restrictions which are
inconsistent with the rights and obligations of the parties under this
Agreement.

7.       License Grants.

         7.1.     ArQule Screening License. Subject to the terms and conditions
of this Agreement, ArQule hereby grants Solvay and its Affiliates a
nonexclusive, worldwide, royalty-free, license (without the right to grant
sublicenses) under ArQule Patent Rights and ArQule Technology to use the ArQule
Compounds during the Research Period to screen for activity against any
biological targets in the Field.

         7.2.     ArQule Commercial License. Effective upon designation by the
Research Committee of an ArQule Compound as a Licensed Compound and the
disclosure by Solvay of the Target and level of activity pursuant to Section
3.6, ArQule hereby grants to Solvay and its Affiliates with respect to each such
Licensed Compound the following licenses in the Field:

         (i)      an exclusive (even as to ArQule), worldwide license (with the
                  right to sublicense) under the ArQule Patent Rights and other
                  rights in ArQule Technology to conduct development of Licensed
                  Compounds, including the right to develop Derivative Compounds
                  based on Licensed Compounds;

         (ii)     an exclusive (even as to ArQule), worldwide license (with the
                  right to sublicense) under the ArQule Patent Rights and other
                  rights in ArQule Technology to make, have made, use, have
                  used, sell and have sold in the Field Licensed Compounds; and

         (iii)    a non-exclusive, worldwide license (with the right to
                  sublicense) under the ArQule Patent Rights and other rights in
                  ArQule Technology to use chemical synthesis methods within the
                  ArQule Patent Rights and ArQule Technology to make
                  Royalty-Bearing Products.

Solvay further acknowledges and agrees that the license grant in clause (iii) of
this Section is subject to the terms, conditions, and limitations of any
agreement under which ArQule has acquired or will acquire rights in a chemical
synthesis method from a third party, which shall be promptly notified by ArQule
to Solvay and, in such event, ArQule may require Solvay to enter into a separate
sublicense agreement before such license grant shall take effect. ArQule

                                       14
<PAGE>

represents and warrants that Solvay will not incur any payment obligation to a
third party as a result of the practice of the license grant set forth in clause
(iii) above for third-party licenses that ArQule has executed prior to the
Effective Date. ArQule covenants that ArQule will seek to obtain such
royalty-free manufacturing licenses as part of its chemistry licenses in the
future. In the event that Solvay decides to sublicense its rights under this
Section to a third party, Solvay shall furnish ArQule with written notice of the
sublicense grant and shall ensure that all sublicense agreements conform to this
Agreement.

                  7.3.     Diligence. Solvay agrees to use reasonable commercial
efforts to develop and market Royalty-Bearing Products based on or incorporating
any Licensed Compound, or Derivative Compounds thereof, using a level of effort
consistent with that used for other Solvay products having similar commercial
potential. The parties hereby acknowledge their understanding that Solvay's
obligations under this Section do not apply to each Licensed Compound in itself,
but only to at least one Licensed Compound or Derivative Compound thereof that
is active against the same Target. Subject to Section 7.5, Solvay shall have the
sole and absolute discretion to make all decisions relating to the research,
development, marketing and other commercialization activities with respect to
any Licensed Compound or its Derivative Compounds or any Royalty-Bearing Product
derived therefrom.

                  7.4.     Reports of Development Progress. Solvay agrees to
keep ArQule informed of its development progress with respect to each Licensed
Compound or Derivative Compound thereof for which it has obtained a license
under Section 7.2 as follows:

                  (a)      Initial Research Plan. Within 60 days after obtaining
a license, Solvay will provide ArQule with a time line of its planned research
activities for that Licensed Compound and will keep ArQule periodically informed
of its progress under such schedule.

                  (b)      Lead Compound. Solvay will notify ArQule of the
designation of any Licensed Compound or Derivative Compounds thereof as a lead
compound that fulfills Solvay's primary criteria in a particular project (e.g.,
potency, selectivity, and bioavailability). Within 60 days of such designation,
Solvay will provide ArQule with a copy of a revised time line of its research
activities for that lead compound and will keep ArQule periodically informed of
its progress under such schedule.

                  (c)      Priority Substance. Solvay will notify ArQule of the
designation of any Licensed Compound or Derivative Compounds thereof as a
Priority Substance. Within 60 days of such designation, Solvay will provide
ArQule with a copy of a revised time line of its research activities for that
Priority Substance and will keep ArQule periodically informed of its progress
under such schedule.

                  (d)      Project Declaration. Solvay will promptly notify
ArQule of a Project Declaration for any Licensed Compound or Derivative
Compounds thereof.

                  (e)      Discontinuation of Development. Solvay agrees to
notify ArQule if it decides to discontinue development or marketing of any
Licensed Compound or Derivative Compounds thereof.

                                       15
<PAGE>

In addition, throughout the term of this Agreement, Solvay will submit to ArQule
annual written reports and semi-annual verbal reports of the activities of
Solvay and its Affiliates with respect to all such compounds during the
reporting period. These reports will include relevant chemical and biological
data and other information sufficient to allow ArQule to determine whether
Solvay and/or its Affiliates are engaging in significant activity with respect
to each such compound prior to Project Declaration. The information in such
reports shall be considered Confidential Information under Section 10.1. hereof.
During the Research Period, Solvay shall provide such reports on a schedule such
that they can be reviewed at the meetings of the Research Committee. In
addition, Solvay agrees to inform ArQule at least once each calendar year
regarding the status of any Solvay Derivative Compounds that Solvay develops
based on Solvay Derivative Compounds synthesized by ArQule under this Agreement.

         7.5.     Reversion of Rights. In the event that (i) Solvay notifies
ArQule pursuant to Section 7.4(e) above that it has determined to discontinue
the development of any Licensed Compound or Derivative Compounds thereof or (ii)
Solvay and/or its Affiliates fail, prior to Project Declaration with respect
thereto, to engage in significant activities for a continuous period of twelve
(12) months with respect to any Licensed Compound, or Derivative Compounds
thereof and significant activities are not resumed within six (6) months of
notice thereof, ArQule shall have the right, immediately upon notice, to
terminate the license granted to Solvay under Section 7.2 with respect to such
Licensed Compound, and ArQule will thereafter be free to grant licenses to third
parties under ArQule Patent Rights and ArQule Technology to make, use, sell and
have sold in the Field products incorporating that Licensed Compound. Any
dispute concerning whether Solvay or its Affiliates have engaged in significant
activity within the meaning of clause (ii) above shall be resolved under the
dispute resolution provisions of Section 13.5.

8.       AMAP Technology.

         Solvay acknowledges that ArQule has fully satisfied and discharged all
of its obligations under Section 8 of the Prior Agreement, except for the
transfer of certain technology that was developed prior to December 31, 2000 and
which the Research Committee has agreed to transfer during calendar year 2001,
as described in Exhibit B (the "2000 Technology"). ArQule will transfer the 2000
Technology to the extent, and in the manner, approved by the Research Committee
and documented in Exhibit B. Solvay may substitute the FTE resources in the
Directed Array Program to this technology transfer activity. For any resource
commitments beyond the FTEs that are reallocated from the Directed Array Program
Solvay shall reimburse ArQule for such activities at the rate of $250,000 per
FTE per year. In all cases Solvay shall reimburse ArQule for out-of - pocket
expenses (e.g., travel) in relation to these activities.

9.       Payments, Reports, and Records.

         9.1.     Access Fee Payments.

                  9.1.1.   Compass Array Library. In partial consideration of
the delivery of the Compass Array Library in accordance with Section 3.2, Solvay
shall pay ArQule the amount of

                                       16
<PAGE>

two hundred thousand dollars ($200,000), payable in four installments of $50,000
within thirty (30) days after Solvay receives each quarterly segment of such
Compass Array Library.

                  9.1.2.   Mapping Array Libraries. In partial consideration of
the delivery of up to ten (10) Mapping Array Libraries during the Research
Period in accordance with Section 3.3, Solvay shall pay ArQule an annual fee in
the amount of three hundred thousand dollars ($300,000), payable as follows:

         $150,000          On the Effective Date
         $150,000          On January 2, 2002

Solvay may obtain access to additional available Mapping Array Libraries during
the Research Period at a cost of fifty thousand dollars ($50,000) per Mapping
Array Library which amount shall be paid to ArQule within thirty (30) days of
shipment.

         9.2      Resynthesis Payments. In consideration of the synthesis and
delivery of resynthesis compounds during the Research Period in accordance with
Section 3.5, Solvay shall pay ArQule two thousand, five hundred dollars ($2,500)
per compound within thirty (30) days of receipt ( for requested resynthesis of
up to twenty-five (25) mg.).

         9.3.     Directed Array Program Payments. In partial consideration of
the performance by ArQule of the DA Program in accordance with Section 4, Solvay
shall pay ArQule at the rate of $250,000 per FTE per year for a total of one
million dollars ($1,000,000) per year. Solvay shall make such annual payment in
advance in equal quarterly installments.

         9.4.     Milestone Payments. In partial consideration of the
performance of the Research Program by ArQule and of the rights granted Solvay
under this Agreement, Solvay shall pay ArQule the following amounts within
thirty (30) days after each occurrence of the following milestones:

         (i)      with respect to a Royalty-Bearing Product containing as one of
                  its constituents any Licensed Compound, ArQule Derivative
                  Compound, as well as with respect to the Prior Agreement any
                  Solvay Derivative Compound, or any other compound discovered
                  or designed by Solvay directly as a result of information
                  obtained by Solvay under the MA Program or DA Program from one
                  or more Licensed Compounds, ArQule Derivative Compounds, or
                  Solvay Derivative Compounds under the Prior Agreement, which
                  information forms the primary basis for such discovery or
                  development and which information was not previously known to
                  Solvay from sources other than ArQule:

                  $2,000,000        Commencement by Solvay, at its own
                                    discretion, of Phase III Clinical Trials
                                    required by the United States Food and Drug
                                    Administration, or the foreign equivalent,
                                    for each Royalty-Bearing Product

                                       17
<PAGE>

                  $3,000,000        First commercial sale of each
                                    Royalty-Bearing Product in any of: United
                                    States; Japan; or, after obtaining EU
                                    registration, Germany, France, or the United
                                    Kingdom. This milestone is payable only once
                                    on the first sale in the first of these
                                    countries, not the first sale in each of
                                    these countries.

         (ii)     with respect to a Royalty-Bearing Product containing as one of
                  its constituents any Solvay Derivative Compound under this
                  Agreement and any other compound discovered or designed by
                  Solvay directly as a result of information obtained by Solvay
                  under the MA Program or DA Program from one or more Solvay
                  Derivative Compounds under this Agreement, which information
                  forms the primary basis for such discovery or development and
                  which information was not previously known to Solvay from
                  sources other than ArQule:

                  $500,000          Commencement by Solvay, at its own
                                    discretion, of Phase II Clinical Trials
                                    required by the United States Food and Drug
                                    Administration, or the foreign equivalent,
                                    for each Royalty-Bearing Product

                  $1,000,000        Commencement by Solvay, at its own
                                    discretion, of Phase III Clinical Trials
                                    required by the United States Food and Drug
                                    Administration, or the foreign equivalent,
                                    for each Royalty-Bearing Product

                  $2,000,000        First commercial sale of each
                                    Royalty-Bearing Product in any of: United
                                    States; Japan; or, after obtaining EU
                                    registration, Germany, France, or the United
                                    Kingdom. This milestone is payable only once
                                    on the first sale in the first of these
                                    countries, not the first sale in each of
                                    these countries.

If a Royalty-Bearing Product contains a compound discovered or designed by
Solvay directly as a result of information obtained by Solvay under the MA
Program or DA Program from (a) one or more Solvay Derivative Compounds under
this Agreement and (b) a Licensed Compound, ArQule Derivative Compound, or
Solvay Derivative Compound under the Prior Agreement (such that the
Royalty-Bearing Product could fall within clause (i) or clause (ii) above), then
the higher milestone payments shall apply. Such milestone payments shall be
non-refundable and shall not be credited against royalties payable to ArQule
under this Agreement. Solvay shall promptly notify ArQule of each occurrence of
either of the foregoing milestones.

         9.5.     Royalties. In partial consideration of the performance of the
Research Program by ArQule and the rights granted to Solvay under this
Agreement, Solvay shall pay to ArQule the following royalty on Net Sales of
Royalty-Bearing Products:

         (i)      two percent (2%) with respect to a Royalty-Bearing Product
                  containing as one of its constituents any Licensed Compound,
                  ArQule Derivative Compound, as well

                                       18
<PAGE>

                  as with respect to the Prior Agreement any Solvay Derivative
                  Compound, or any other compound discovered or designed by
                  Solvay directly as a result of information obtained by Solvay
                  under the MA Program or DA Program from one or more Licensed
                  Compounds, ArQule Derivative Compounds, or Solvay Derivative
                  Compounds under the Prior Agreement, which information forms
                  the primary basis for such discovery or development and which
                  information was not previously known to Solvay from sources
                  other than ArQule; or

         (ii)     one percent (1%) with respect to a Royalty-Bearing Product
                  containing as one of its constituents any Solvay Derivative
                  Compound under this Agreement and any other compound
                  discovered or designed by Solvay directly as a result of
                  information obtained by Solvay under the MA Program or DA
                  Program from one or more Solvay Derivative Compounds under
                  this Agreement, which information forms the primary basis for
                  such discovery or development and which information was not
                  previously known to Solvay from sources other than ArQule.

If a Royalty-Bearing Product contains a compound discovered or designed by
Solvay directly as a result of information obtained by Solvay under the MA
Program or DA Program from (a) one or more Solvay Derivative Compounds under
this Agreement and (b) a Licensed Compound, ArQule Derivative Compound, or
Solvay Derivative Compound under the Prior Agreement (such that the
Royalty-Bearing Product could fall within clause (i) or clause (ii) above), then
the higher royalty rate shall apply. Such royalty shall be payable on a
country-by-country basis for as long as a Royalty-Bearing Product is covered by
a Valid Claim of a Patent Right.

         9.6.     Other Milestone and Royalty Payments. The parties shall
negotiate in good faith the commercially reasonable financial terms pertaining
to payments for achievement of development milestones relating to
Royalty-Bearing Products and for a royalty on Royalty-Bearing Products for uses
within the Field other than as a human therapeutic, which terms shall be set
forth in a separate agreement and shall be no higher than those set forth in
Sections 9.4. and 9.5. above. Solvay shall not develop or sell a Royalty-Bearing
Product for uses within the Field other than as a human therapeutic until such
agreement is executed by both parties.

         9.7.     Reports and Payments. Within thirty (30) days after the
conclusion of each Royalty Period, Solvay shall deliver to ArQule a report
containing the following information:

                           (a)      gross sales of Royalty-Bearing Products by
         Solvay and its Affiliates and sublicensees during the applicable
         Royalty Period in each country of sale;

                           (b)      calculation of Net Sales for the applicable
         Royalty Period in each country of sale; and

                           (c)      total Net Sales in U.S. dollars, together
         with the exchange rates used for conversion.

All such reports shall be maintained in confidence by ArQule. If no royalties
are due to ArQule for any reporting period, the report shall so state.
Concurrent with this report, Solvay shall remit

                                       19
<PAGE>

to ArQule any payment due for the applicable Royalty Period. The method of
payment shall be mutually agreed to. All amounts payable to ArQule under this
Section will first be calculated in the currency of sale and then converted into
U.S. dollars in accordance with Section 9.8.

         9.8.     Invoices; Payments in U.S. Dollars. With the exception of
royalty payments due under Section 9.5, ArQule shall submit invoices to Solvay
for each payment due ArQule hereunder, and Solvay shall pay such invoices within
thirty (30) days of receipt thereof. All payments due under this Agreement
shall, except as provided in Section 9.9 below, be payable in United States
dollars. Conversion of foreign currency to U.S. dollars shall be made at the
conversion rate existing in the United States (as reported in the Wall Street
Journal) on the last working day of the calendar quarter preceding the
applicable calendar quarter. Such payments shall be without deduction of
exchange, collection, or other charges.

         9.9.     Payments in Other Currencies. If by law, regulation, or fiscal
policy of a particular country, conversion into United States dollars or
transfer of funds of a convertible currency to the United States is restricted
or forbidden, Solvay shall give ArQule prompt written notice of such
restriction, which notice shall satisfy the thirty-day payment deadline
described in Section 9.7. Solvay shall pay any amounts due ArQule through
whatever lawful methods ArQule reasonably designates; provided, however, that if
ArQule fails to designate such payment method within thirty (30) days after
ArQule is notified of the restriction, then Solvay may deposit such payment in
local currency to the credit of ArQule in a recognized banking institution
selected by Solvay and identified by written notice to ArQule, and such deposit
shall fulfill all obligations of Solvay to ArQule with respect to such payment.

         9.10.    Records. Solvay and its Affiliates shall maintain complete and
accurate records of Royalty-Bearing Products made, used or sold by them or their
sublicensees under this Agreement, and any amounts payable to ArQule in relation
to such Royalty-Bearing Products, which records shall contain sufficient
information to permit ArQule to confirm the accuracy of any reports delivered to
ArQule in accordance with Section 9.7. The relevant party shall retain such
records relating to a given Royalty Period for at least three (3) years after
the conclusion of that Royalty Period.

         ArQule will maintain complete and accurate records of the activities
engaged in by the ArQule FTEs, which records shall contain sufficient
information to permit Solvay to confirm the compliance of ArQule with Section 4.

         Each party (acting as the "Auditing Party") shall have the right, at
its own expense, to cause an independent, certified public accountant to inspect
such records of the other party (the "Audited Party") during normal business
hours for the sole purpose of verifying any reports and payments delivered under
this Agreement. Such accountant shall not disclose to the Auditing Party any
information other than information relating to accuracy of reports and payments
delivered under this Agreement and shall provide the Audited Party with a copy
of any report given to the Auditing Party. The parties shall reconcile any
underpayment or overpayment within thirty (30) days after the accountant
delivers the results of the audit. In the event that any audit performed under
this Section reveals an underpayment in excess of five percent (5%) in any
Royalty Period, the Audited Party shall bear the full cost of such audit. Each
party may

                                       20
<PAGE>

exercise its rights under this Section only once every year and only with
reasonable prior notice to the other party.

         9.11.    Late Payments. Any payments by Solvay that are not paid on or
before the date such payments are due under this Agreement shall bear interest,
to the extent permitted by law, at two percentage points above the Federal
Reserve Bank discount rate on the last day of the month the payments are due,
calculated based on the number of days that payment is delinquent.

         9.12.    Withholding Taxes. Any tax required to be withheld by Solvay
or any Affiliate or sublicensee under the laws of any foreign country for the
account of ArQule under this Article 9 shall be promptly paid by Solvay or said
Affiliate or sublicensee for and on behalf of ArQule to the appropriate
governmental authority, and Solvay or the Affiliate or sublicensee shall furnish
ArQule with proof of payment of such tax together with official or other
appropriate evidence issued by the appropriate governmental authority sufficient
to enable ArQule to support a claim for income tax credit in respect of any sum
so withheld.

10.      Confidential Information and Proprietary Materials.

         10.1.    Confidential Information.

                  10.1.1.  Definition of Confidential Information. Confidential
Information shall mean any technical or business information furnished by one
party (the "Disclosing Party") to the other party (the "Receiving Party") in
connection with this Agreement and specifically designated as confidential. Such
Confidential Information may include, without limitation, the identity of or
other information pertaining to Proprietary Materials, the identity of a
chemical compound, the use of a chemical compound, trade secrets, know-how,
inventions, technical data or specifications, testing methods, business or
financial information, research and development activities, product and
marketing plans, and customer and supplier information. The parties expressly
agree that the structures of Active Compounds and the identity of the related
Target shall be considered Confidential Information until such time as the
parties have mutually agreed to disclose such information in patent filings
pursuant to Section 6.3.

                  10.1.2.  Designation of Confidential Information. Confidential
Information that is disclosed in writing shall be marked with a legend
indicating its confidential status. Confidential Information that is disclosed
orally or visually shall be documented in a written notice prepared by the
Disclosing Party and delivered to the Receiving Party within thirty (30) days of
the date of disclosure; such notice shall summarize the Confidential Information
disclosed to the Receiving Party and reference the time and place of disclosure.

                  10.1.3.  Obligations. The Receiving Party agrees that it
shall:

                           (a)      maintain all Confidential Information in
         strict confidence, except that the Receiving Party may disclose or
         permit the disclosure of any Confidential Information to its, and its
         Affiliates, directors, officers, employees, consultants, Solvay
         sublicensees, and advisors who are obligated to maintain the
         confidential nature of such

                                       21
<PAGE>

         Confidential Information and who need to know such Confidential
         Information for the purposes set forth in this Agreement;

                           (b)      use all Confidential Information solely for
         the purposes set forth in, or as permitted by, this Agreement; and

                           (c)      allow its directors, officers, employees,
         consultants, and advisors to reproduce the Confidential Information
         only to the extent necessary to effect the purposes set forth in this
         Agreement, with all such reproductions being considered Confidential
         Information.

                  10.1.4.  Exceptions. The obligations of the Receiving Party
under Section 10.1.3 above shall not apply to the extent that the Receiving
Party can demonstrate that certain Confidential Information:

                           (a)      was in the public domain prior to the time
         of its disclosure under this Agreement;

                           (b)      entered the public domain after the time of
         its disclosure under this Agreement through means other than an
         unauthorized disclosure resulting from an act or omission by the
         Receiving Party;

                           (c)      was independently developed or discovered by
         the Receiving Party without use of the Confidential Information;

                           (d)      is or was disclosed to the Receiving Party
         at any time, whether prior to or after the time of its disclosure under
         this Agreement, by a third party having no fiduciary relationship with
         the Disclosing Party and having no obligation of confidentiality to the
         Disclosing Party with respect to such Confidential Information; or

                           (e)      is required to be disclosed to comply with
         applicable laws or regulations (such as disclosure to the United States
         Food and Drug Administration or the United States Patent and Trademark
         Office or to their foreign equivalents), or to comply with a court or
         administrative order, provided that the Disclosing Party receives prior
         written notice of such disclosure and that the Receiving Party takes
         all reasonable and lawful actions to obtain confidential treatment for
         such disclosure and, if possible, to minimize the extent of such
         disclosure.

         10.2.    Proprietary Materials.

                  10.2.1.  Definition of Proprietary Materials. Proprietary
Materials shall mean any tangible chemical, biological, or physical research
materials that are furnished by one party (the "Transferring Party") to the
other party (the "Receiving Party") in connection with this Agreement regardless
of whether such materials are specifically designated as proprietary to the
Transferring Party. Proprietary Materials shall include, without limitation, all
ArQule

                                       22
<PAGE>

Compounds, ArQule Derivative Compounds, Solvay Compounds and Solvay Derivative
Compounds..

                  10.2.2.  Limited Use. The Receiving Party shall use
Proprietary Materials solely for the purposes set forth in this Agreement. The
Receiving Party shall use the Proprietary Materials only in compliance with all
applicable governmental laws and regulations.

                  10.2.3.  Limited Disposition. The Receiving Party shall not
transfer or distribute any Proprietary Materials to any third party, except to
its Affiliates, without the prior written consent of the Transferring Party.

                  10.2.4.  Reverse Engineering. Solvay shall not attempt to
reverse engineer, or attempt to determine the structure of, any ArQule Compound
until the structure of such compound has been disclosed to Solvay by ArQule
following notification by Solvay of the location of an Active Compound pursuant
to Sections 3.3. and 3.4.

         10.3.    Return of Confidential Information and Proprietary Materials.
Upon the termination of this Agreement, at the request of the Disclosing Party,
the Receiving Party shall destroy or return to the Disclosing Party all
originals, copies, and summaries of documents, materials, and other tangible
manifestations of Confidential Information in the possession or control of the
Receiving Party, except that the Receiving Party may retain one copy of the
Confidential Information in the possession of its legal counsel (for ArQule) and
its Legal and Trademarks Department (for Solvay) solely for the purpose of
monitoring its obligations under this Agreement. Upon the termination of this
Agreement, the Receiving Party shall at the instruction of the Transferring
Party either destroy or return any unused Proprietary Materials.

         10.4.    Publications. In the event that either party desires to
publicly disclose (through journals, lectures, or otherwise) any results
relating to the Research Programs, such party (the "Publishing Party") shall
furnish the other party (the "Reviewing Party") with (i) a copy of any written
publication at least sixty (60) days prior to submission or (ii) a summary or
abstract of an oral disclosure at least thirty (30) days prior to the intended
disclosure date. The Reviewing Party shall have the right to (i) consent to the
disclosure with modifications to protect patentable inventions or prevent
disclosure of Confidential Information, (ii) delay the disclosure for a period
of ninety (90) days to enable the preparation and filing of a patent
application, or (iii) refuse to allow the disclosure in order to maintain
certain information as a trade secret, which refusal shall not be unreasonably
exercised. Any disagreements arising under this Section shall be referred to the
Research Committee.

         10.5.    Survival of Obligations. The obligations set forth in this
Article shall remain in effect for a period of five (5) years after termination
of this Agreement, except that the obligations of the Receiving Party to return
or destroy Confidential Information to the Disclosing Party and to return or
destroy Proprietary Materials received from the Transferring Party shall survive
until fulfilled.

                                       23
<PAGE>

11.      Indemnification and Insurance.

         11.1.    Indemnification. Each party (the "Indemnitor") shall
indemnify, defend, and hold harmless the other party and its Affiliates and
their directors, officers, employees, and agents and their respective
successors, heirs and assigns (the "Indemnitees"), against any liability,
damage, loss, or expense (including reasonable attorneys fees and expenses of
litigation) incurred by or imposed upon the Indemnitees or any one of them in
connection with any claims, suits, actions, demands, or judgments arising out of
any theory of product liability (including, but not limited to, actions in the
form of tort, warranty, or strict liability) concerning any product (or any
process or service) that is made, used, or sold by such other party pursuant to
any right or license granted under this Agreement or arising out of any breach
of a representation or warranty under this Agreement; provided, however, that
such indemnification right shall not apply to any liability, damage, loss, or
expense to the extent directly attributable to the negligent activities,
reckless misconduct, or intentional misconduct of the Indemnitees.

         11.2.    Procedures. Any Indemnitee that intends to claim
indemnification under Section 11.1 shall promptly notify the appropriate
Indemnitor of any claim in respect of which the Indemnitee intends to claim such
indemnification, and the Indemnitor shall assume the defense thereof with
counsel selected by the Indemnitor (Indemnitor shall consult with Indemnitee
with respect to a possible conflict of interest of such counsel retained by
Indemnitor); provided, however, that an Indemnitee shall have the right to
retain its own counsel at its cost; provided, further, that if representation of
such Indemnitee by the counsel retained by the Indemnitor would be inappropriate
due to actual or potential conflict of interest between such Indemnitee and any
other party represented by such counsel in such proceedings, the Indemnitor and
Indemnitee will each pay an equal share of the costs of the Indemnitee. The
indemnity agreement in Section 11.1. shall not apply to amounts paid in
settlement of any loss, claim, liability or action if such settlement is
effected without the consent of Solvay, which consent shall not be withheld
unreasonably. The failure to deliver notice to the Indemnitor within a
reasonable time after the commencement of any such action, if prejudicial to its
ability to defend such action, shall relieve the Indemnitor of any liability to
the Indemnitee under Section 11.1. Each party and its Affiliates and their
employees and agents shall cooperate fully with the other party and its legal
representatives in the investigation of any action, claim or liability covered
by this indemnification.

         11.3.    Insurance. Each party shall maintain reasonably adequate
insurance or self-insurance coverage for its own potential liabilities to the
Indemnitees as set forth in this Article.

12.      Term and Termination.

         12.1.    Term. This Agreement shall commence on the Effective Date and
shall remain in effect until the expiration of the Research Period, unless
earlier terminated as provided in this Article 12.

         12.2.    Breach of Payment Obligations. In the event that Solvay fails
to make timely payment of any amounts due to ArQule under this Agreement, ArQule
may terminate this Agreement upon thirty (30) days written notice to Solvay,
unless Solvay (i) pays all past-due

                                       24
<PAGE>

amounts within such thirty-day notice period or (ii) invokes dispute resolution
under Section 13.5. within such thirty-day notice period.

         12.3.    Material Breach. In the event that either party commits a
material breach of any of its obligations under this Agreement and such party
fails (i) to remedy that breach within ninety (90) days after receiving written
notice thereof from the other party or (ii) to commence dispute resolution
pursuant to Section 13.5., within ninety (90) days after receiving written
notice of that breach from the other party, the other party may immediately
terminate this Agreement upon written notice to the breaching party.

         12.4.    Effect of Termination. The following provisions shall survive
the expiration or termination of this Agreement: Articles 5, 10, and 11;
Sections 3.9, 6.1 through 6.4, 6.6, 7.2 through 7.5, 9.4 through 9.12, 12.4,
13.3, 13.4, 13.5, and 13.10.

13.      Miscellaneous.

         13.1.    Relationship of Parties. Nothing in this Agreement is intended
or shall be deemed to constitute a partnership, agency, employer-employee or
joint venture relationship between the parties. No party shall incur any debts
or make any commitments for the other, except to the extent, if at all,
specifically provided therein.

         13.2.    Publicity. Neither party shall use the name of the other party
or reveal the terms of this Agreement in any publicity or advertising without
the prior written approval of the other party, except that (i) either party may
use the text of a written statement approved in advance by both parties without
further approval, (ii) either party shall have the right to identify the other
party and to disclose the terms of this Agreement as required by applicable
securities laws or other applicable law or regulation, and (iii) either party
may use the name of the other party and reveal the existence of this Agreement.

         13.3.    Non-Solicitation. During the term of this Agreement and
thereafter for a period of two (2) years, each party agrees not to seek to
persuade or induce any employee of the other party to discontinue his or her
employment with that party in order to become employed by or associated with any
business, enterprise, or effort that is associated with its own business.

         13.4.    Governing Law. The License Agreement shall be governed by and
construed in accordance with the laws of England.

         13.5.    Dispute Resolution Procedures.

                           (a)      The parties hereby agree that they will
         attempt in good faith to resolve any controversy, claim or dispute
         ("Dispute") arising out of or relating to this Agreement promptly by
         negotiations. Any such Dispute which is not settled by the parties
         within fifteen (15) days after notice of such Dispute is given by one
         party to the other in writing shall be referred to a senior executive
         of ArQule and the Vice President-Research of Solvay who are authorized
         to settle such Disputes on behalf of their respective companies
         ("Senior Executives"). The Senior Executives will meet for

                                       25
<PAGE>

         negotiations within fifteen (15) days of the end of the 15 day
         negotiation period referred to above, at a time and place mutually
         acceptable to both Senior Executives. If the Dispute has not been
         resolved within thirty (30) days after the end of the 15 day
         negotiation period referred to above (which period may be extended by
         mutual agreement), subject to any rights to injunctive relief and
         unless otherwise specifically provided for herein, any Dispute will be
         settled first by non-binding mediation and thereafter by binding
         arbitration as described in subsections (b) and (c) below.

                           (b)      Any Dispute which is not resolved by the
         parties within the time period described in subsection (a) shall be
         submitted to an alternative dispute resolution process ("ADR"). Within
         five (5) business days after the expiration of the thirty (30) day
         period set forth in subsection (a), each party shall select for itself
         a representative with the authority to bind such party and shall notify
         the other party in writing of the name and title of such
         representative. Within ten (10) business days after the date of
         delivery of such notice, the representatives shall schedule a date for
         engaging in non-binding ADR with a neutral mediator or dispute
         resolution firm mutually acceptable to both representatives. Any such
         mediation shall be held in London, England. Thereafter, the
         representatives of the parties shall engage in good faith in an ADR
         process under the auspices of such individual or firm. If the
         representatives of the parties have not been able to resolve the
         Dispute within thirty (30) business days after the conclusion of the
         ADR process, or if the representatives of the parties fail to schedule
         a date for engaging in non-binding ADR within the ten (10) day period
         set forth above, the Dispute shall be settled by binding arbitration as
         set forth in subsection (c) below. If the representatives of the
         parties resolve the dispute within the thirty (30) day period set forth
         above, then such resolution shall be binding upon the parties. If
         either party fails to abide by such resolution, the other party can
         immediately refer the matter to arbitration under Section 13.5(c).

                           (c)      If the parties have not been able to resolve
         the Dispute as provided in subsections (a) and (b) above, the Dispute
         shall be finally settled by binding arbitration. Any arbitration
         hereunder shall be conducted under the Rules of Arbitration of the
         International Chamber of Commerce. The arbitration shall be conducted
         in the English language before three arbitrators chosen according to
         the following procedure: each of the parties shall appoint one
         arbitrator and the two so nominated shall choose the third. If the
         arbitrators chosen by the parties cannot agree on the choice of the
         third arbitrator within a period of thirty (30) days after their
         appointment, then the third arbitrator shall be appointed by the Court
         of Arbitration of the International Chamber of Commerce. Any such
         arbitration shall be held in London, England. The arbitrators shall
         have the authority to grant specific performance, and to allocate
         between the parties the costs of arbitration in such equitable manner
         as they determine. The arbitral award (i) shall be final and binding
         upon the parties; and (ii) may be entered in any court of competent
         jurisdiction in accordance with the 1958 Convention on the Recognition
         and Enforcement of Arbitral Awards.

                           (d)      Nothing contained in this Section or any
         other provisions of this Agreement shall be construed to limit or
         preclude a party from bringing any action in any

                                       26
<PAGE>

         court of competent jurisdiction for injunctive or other provisional
         relief to compel the other party to comply with its obligations
         hereunder before or during the pendency of mediation or arbitration
         proceedings. The parties hereby irrevocably consent to submit to the
         jurisdiction of the courts of England and/or any other court having
         jurisdiction for this purpose.

         13.6.    Counterparts. This Agreement may be executed in one or more
counterparts, each of which shall be deemed an original, and all of which
together shall be deemed to be one and the same instrument.

         13.7.    Headings. All headings in this Agreement are for convenience
only and shall not affect the meaning of any provision hereof.

         13.8.    Binding Effect. This Agreement shall inure to the benefit of
and be binding upon the parties, their Affiliates, and their respective lawful
successors and assigns.

         13.9.    Assignment. This Agreement may not be assigned by either party
without the prior written consent of the other party, except that either party
may assign this Agreement to a successor in connection with the merger,
consolidation, or sale of all or substantially all of its assets or that portion
of its business pertaining to the subject matter of this Agreement.

         13.10.   Notices. All notices, requests, demands and other
communications required or permitted to be given pursuant to this Agreement
shall be in writing and shall be deemed to have been duly given upon the date of
receipt if delivered by hand, recognized international overnight courier,
confirmed facsimile transmission, or registered or certified mail, return
receipt requested, postage prepaid to the following addresses or facsimile
numbers:

If to Solvay:                       If to ArQule:

Solvay Pharmaceuticals B.V.         ArQule, Inc.
C.J. van Houtenlaan 36              19 Presidential Way
1381 CP Weesp                       Woburn, MA  01801
The Netherlands                     Attention:  President
Attention:                          Tel: (781) 994-0300
Manager Technology Development      Fax: (781) 503-0009

Tel: +31 294 479696
Fax: +31 294 477148

with a copy to:                     with a copy to:

Same Address                        Same Address
Attention: Head Legal Department    Attention:  General Counsel
Tel: +31 294 477479                 Tel: (781) 994-0300
Fax: +31 294 477126                 Fax: (781) 503-0009

                                       27
<PAGE>

Either party may change its designated address and facsimile number by notice to
the other party in the manner provided in this Section.

         13.11.   Amendment and Waiver. This Agreement may be amended,
supplemented, or otherwise modified only by means of a written instrument signed
by both parties. Any waiver of any rights or failure to act in a specific
instance shall relate only to such instance and shall not be construed as an
agreement to waive any rights or fail to act in any other instance, whether or
not similar.

         13.12.   Severability. In the event that any provision of this
Agreement shall, for any reason, be held to be invalid or unenforceable in any
respect, such invalidity or unenforceability shall not affect any other
provision hereof, and the parties shall negotiate in good faith to modify the
Agreement to preserve (to the extent possible) their original intent.

         13.13.   Entire Agreement. This Agreement constitutes the entire
agreement between the parties with respect to the subject matter hereof and
supersedes all prior agreements or understandings between the parties relating
to the subject matter hereof, including without limitation the Prior Agreement.

         13.14.   Hardship. The underlying objective of this Agreement is to
realize in an economical and reasonable way the mutual interests and
requirements of the parties. If at any time this Agreement should no longer meet
this objective because of technical developments, economic developments or
political changes that could not reasonably be foreseen at the time of signing
this Agreement thus causing undue and prolonged hardship, the parties shall meet
in order to bring about a mutually agreeable solution according to the economic
and reasonable objectives of this Agreement.

         13.15.   Force Majeure. Neither party shall be held liable or
responsible to the other party, nor be deemed to be in breach of this Agreement,
for failure or delay in fulfilling or performing any provisions of this
Agreement when such failure or delay is caused by or results from any cause
whatsoever outside the reasonable control of the party concerned including, but
not limited to, fire, explosion, breakdown of plant, strike, lock-out, labor
disputes, casualty or accident, lack or failure of transportation facilities,
flood, lack or failure of sources of supply or of labor, raw materials or
energy, civil commotion, blockage or embargo, any law, regulation, decision,
demand or requirement of any national or local government or authority. The
party claiming relief shall, without delay, notify the other party by registered
airmail or by telefax of the interruption and cessation thereof and shall use
its best efforts to remedy the effects of such hindrance with all reasonable
dispatch. The onus of proving that any such Force Majeure event exists shall
rest upon the party so asserting. During the period that one party is prevented
from performing its obligations under this Agreement due to a Force Majeure
event, the other party may, in its sole discretion, suspend any obligations that
relate thereto. Upon cessation of such Force Majeure event the parties hereto
shall use their best efforts to make up for any suspended obligations. If such
Force Majeure event is anticipated to continue, or has existed for nine (9)
consecutive months or more, this Agreement may be forthwith terminated by either
party by registered airmail or by telefax. In case of such termination the
terminating party will not be required to pay to the other party any indemnity
whatsoever.

                                       28
<PAGE>

         IN WITNESS WHEREOF, the undersigned have duly executed and delivered
this Agreement as a sealed instrument effective as of the date first above
written.

         SOLVAY PHARMACEUTICALS  BV                ARQULE, INC.

         By:__________________________             By:__________________________
              E.A.A.M. Koopmans                          Stephen A. Hill, M.D.
              President, Solvay Pharmaceuticals BV,      President and Chief
               Weesp                                      Executive Officer

         By:__________________________
              Prof. S.G. Schaefer
              Vice President Global Research
              Solvay Pharmaceuticals

                                       29

<PAGE>

                                    EXHIBIT A

                             Compound Specifications

1.       Compass Array Library.

The Compass Array Library is a diverse subset of approximately 25,000 compounds
that have been computationally selected to represent at least 12.5% of the
ArQule Compounds in the Mapping Array Libraries that ArQule produces 2001.

ArQule will provide approximately 100 micrograms of each Compass Array Library
compound dissolved in 25 microliters of 100% DMSO at a concentration of 10 mM in
96-well plates, with 80 filled wells per plate. Because ArQule performs 25%
quality control analysis of each Mapping Array Library corresponding to the
Compass Array Library, the purity and confirmation of molecular weight is
similar to the Mapping Array Library, as described below.

2.       Mapping Array Libraries.

A Mapping Array Library is an Array of ArQule Compounds that ArQule generally
makes available to its collaborators for screening on a non-exclusive basis.
Each Mapping Array Library is based upon a single Chemical Theme.

ArQule will provide approximately 1mg of each Mapping Array Library compound
dissolved in 250 microliters of 100% DMSO at a concentration of 10 mM. The
compounds will be provided in 96-well plates with up to 80 filled wells per
plate. ArQule performs 25% quality control analysis of each Mapping Array
Library by HPLC/UV/ELSD for purity and flow injection mass spectrometry for
confirmation of molecular weight. Each Mapping Array Library is on average more
than 85% pure as determined by HPLC analysis. A Markush structure file defining
each chemical theme is supplied with every shipment.

3.       Confirmation Samples and Resynthesized Compounds.

As determined by the Research Committee, ArQule shall resynthesize and deliver
to Solvay up to twenty-five (25) mg of any Active Compound. ArQule will provide
each resynthesized Compound as a dry, solid power or oil with a purity of 95%
based on HPLC/UV, ELSD. Typically, resynthesis compounds consist of preparative
HPLC-purified, dry, solid compound supplied with proton NMR and mass
spectrometry data.

4.       Directed Array Compounds.

Unless otherwise agreed to by the Research Committee, all ArQule Compounds
delivered as part of the Directed Array Libraries will be provided as 30 mmol of
compound in DMSO in 96-well plates with up to 80 filled wells per plate. ArQule
performs 100% quality control analysis of each Directed Array compound tested by
HPLC/UV/ELSD. The average purity of each Directed

                                       30
<PAGE>

Array Library is 85% as determined by HPLC analysis. An SD file is supplied with
every shipment.
<PAGE>

                                    EXHIBIT B

                            AMAP Technology Transfer

List of 2000 Technology to be transferred and implemented in 2001

1.   CRS-WAD Technology Transfer

2.   Implement process for Solvay to allow direct procurement of fine mechanical
     parts

3.       a. Supply of source code for all Instrument Control Application via CD
         or FTP site (No documentation of source code)

         b. Make LLE quantitation and APD/LLE quantitation operational

4.   New Septum Piercing Technology for OCS

5.   Modifications to LLE 32-bit application modifications

6.   Update WAD.exe with modified rack sequence

7.   Transfer TOCS software

8.   AIMS Feasibility Study to be completed by March 15, 2001

9.   Transfer Solid Phase Synthesis prototype application

10.  Supply electronic documentation for all sections of the binders previously
     delivered to Solvay.

11.  Transfer existing Culling and Reformatting application to Solvay

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00062-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00062-of-00352.parquet"}]]